{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T14:53:33Z","timestamp":1778165613155,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100001188","name":"Jerome Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007133","name":"Buck Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007133","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["T32-AR048522"],"award-info":[{"award-number":["T32-AR048522"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options in Rheum"],"DOI":"10.1007\/s40674-021-00174-1","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T07:02:27Z","timestamp":1617001347000},"page":"150-160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Therapeutic Management of Immune-Mediated Necrotizing Myositis"],"prefix":"10.1007","volume":"7","author":[{"given":"Emma","family":"Weeding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4749-870X","authenticated-orcid":false,"given":"Eleni","family":"Tiniakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"174_CR1","first-page":"1615","volume":"19","author":"AA Amato","year":"2013","unstructured":"Amato AA, Greenberg SA. Inflammatory myopathies. CONTINUUM: Lifelong Learn Neurol. 2013;19:1615\u201333.","journal-title":"CONTINUUM: Lifelong Learn Neurol"},{"issue":"18","key":"174_CR2","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. Longo DL, editor. N Engl J Med. 2015;372(18):1734\u201347.","journal-title":"N Engl J Med"},{"issue":"3","key":"174_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.nmd.2014.12.001","volume":"25","author":"JL De Bleecker","year":"2015","unstructured":"De Bleecker JL, De Paepe B, Aronica E, de Visser M, Amato A, Aronica E, et al. 205th ENMC international workshop: pathology diagnosis of idiopathic inflammatory myopathies Part II 28\u201330 March 2014, Naarden, The Netherlands. Neuromuscular Disorders. 2015;25(3):268\u201372.","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"174_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","volume":"28","author":"Y Allenbach","year":"2018","unstructured":"\u2022\u2022 Allenbach Y, Mammen AL, Benveniste O, Stenzel W. Immune-mediated necrotizing myopathies working group. 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord. 2018;28(1):87\u201399 This study includes the recommendation of the IMNM Working Group regarding definition, diagnosis, and possible treatment of IMNM based on expert opinion and review of current literature.","journal-title":"Neuromuscul Disord"},{"issue":"Pt 8","key":"174_CR5","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/brain\/aww054","volume":"139","author":"Y Allenbach","year":"2016","unstructured":"Allenbach Y, Keraen J, Bouvier A-M, Jooste V, Champtiaux N, Hervier B, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016;139(Pt 8):2131\u20135.","journal-title":"Brain."},{"issue":"9","key":"174_CR6","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","volume":"72","author":"CD Kassardjian","year":"2015","unstructured":"Kassardjian CD, Lennon VA, Alfugham NB, Mahler M, Milone M. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol. 2015;72(9):996\u20131003.","journal-title":"JAMA Neurol"},{"key":"174_CR7","doi-asserted-by":"crossref","unstructured":"Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007 Feb;17(2):194\u2013200.","DOI":"10.1016\/j.nmd.2006.10.007"},{"issue":"2","key":"174_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.21486","volume":"41","author":"P Grable-Esposito","year":"2010","unstructured":"Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010;41(2):185\u201390.","journal-title":"Muscle Nerve"},{"issue":"9","key":"174_CR9","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1002\/art.27572","volume":"62","author":"L Christopher-Stine","year":"2010","unstructured":"Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757\u201366.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"174_CR10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/art.30156","volume":"63","author":"AL Mammen","year":"2011","unstructured":"Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713\u201321.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"174_CR11","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1002\/art.34673","volume":"64","author":"JL Werner","year":"2012","unstructured":"Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64(12):4087\u201393.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"174_CR12","doi-asserted-by":"publisher","first-page":"e0141616","DOI":"10.1371\/journal.pone.0141616","volume":"10","author":"Y Ge","year":"2015","unstructured":"Ge Y, Lu X, Peng Q, Shu X, Wang G. Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS One. 2015;10(10):e0141616.","journal-title":"PLoS One"},{"key":"174_CR13","doi-asserted-by":"crossref","unstructured":"Watanabe Y, Suzuki S, Nishimura H, Murata K, Kurashige T, Ikawa M, et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine (Baltimore). 2015 Jan;94(4):e416.","DOI":"10.1097\/MD.0000000000000416"},{"issue":"5","key":"174_CR14","first-page":"787","volume":"56","author":"E Tiniakou","year":"2017","unstructured":"Tiniakou E, Pinal-Fernandez I, Lloyd TE, Albayda J, Paik J, Werner JL, et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford). 2017;56(5):787\u201394.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"174_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/MD.0000000000000028","volume":"93","author":"Y Allenbach","year":"2014","unstructured":"Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore). 2014;93(3):150\u20137.","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"174_CR16","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/art.1780330908","volume":"33","author":"IN Targoff","year":"1990","unstructured":"Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990;33(9):1361\u201370.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"174_CR17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","volume":"73","author":"T Miller","year":"2002","unstructured":"Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry. 2002;73(4):420\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"174_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/art.11484","volume":"50","author":"AH Kao","year":"2004","unstructured":"Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 2004;50(1):209\u201315.","journal-title":"Arthritis Rheum"},{"key":"174_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","volume":"10","author":"S Suzuki","year":"2015","unstructured":"Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis. 2015;10:61.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"174_CR20","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","volume":"87","author":"Y Watanabe","year":"2016","unstructured":"Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayama K, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016;87(10):1038\u201344.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"174_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/CND.0000000000000065","volume":"16","author":"C Quinn","year":"2015","unstructured":"Quinn C, Salameh JS, Smith T, Souayah N. Necrotizing myopathies: an update. J Clin Neuromuscul Dis. 2015;16(3):131\u201340.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"6","key":"174_CR22","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/BOR.0000000000000335","volume":"28","author":"I Pinal-Fernandez","year":"2016","unstructured":"Pinal-Fernandez I, Mammen AL. Spectrum of immune-mediated necrotizing myopathies and their treatments. Curr Opin Rheumatol. 2016;28(6):619\u201324.","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"174_CR23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/annrheumdis-2016-210198","volume":"76","author":"I Pinal-Fernandez","year":"2017","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, Lahouti AH, Basharat P, Albayda J, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis. 2017;76(4):681\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"174_CR24","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","volume":"40","author":"FW Miller","year":"2001","unstructured":"Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2001;40(11):1262\u201373.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"174_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/art.21715","volume":"55","author":"H Alexanderson","year":"2006","unstructured":"Alexanderson H, Broman L, Tollb\u00e4ck A, Josefson A, Lundberg IE, Stenstr\u00f6m CH. Functional index-2: validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum. 2006;55(1):114\u201322.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"174_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3899\/jrheum.161183","volume":"45","author":"H Alexanderson","year":"2018","unstructured":"Alexanderson H, Regardt M, Ottosson C, Alemo Munters L, Dastmalchi M, Dani L, et al. Muscle strength and muscle endurance during the first year of treatment of polymyositis and dermatomyositis: a prospective study. J Rheumatol. 2018;45(4):538\u201346.","journal-title":"J Rheumatol"},{"issue":"5","key":"174_CR27","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/art.22780","volume":"57","author":"H Alexanderson","year":"2007","unstructured":"Alexanderson H, Dastmalchi M, Esbj\u00f6rnsson-Liljedahl M, Opava CH, Lundberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum. 2007;57(5):768\u201377.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"174_CR28","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s10067-014-2821-x","volume":"34","author":"BY Hanaoka","year":"2015","unstructured":"Hanaoka BY, Cleary LC, Long DE, Srinivas A, Jenkins KA, Bush HM, et al. Physical impairment in patients with idiopathic inflammatory myopathies is associated with the American College of Rheumatology functional status measure. Clin Rheumatol. 2015;34(11):1929\u201337.","journal-title":"Clin Rheumatol"},{"key":"174_CR29","doi-asserted-by":"crossref","unstructured":"Amici DR, Pinal-Fernandez I, Pagkatipunan R, Mears A, De Lorenzo R, Tiniakou E, et al. Muscle endurance deficits in myositis patients despite normal manual muscle testing scores. Muscle Nerve. 2018; This study demonstrates the limitations of the MMT in patients with normal or near-normal muscle strength.","DOI":"10.1002\/mus.26307"},{"key":"174_CR30","doi-asserted-by":"crossref","unstructured":"Dimachkie MM, Barohn RJ, Amato AA. Idiopathic inflammatory myopathies. Neurol Clin. 2014;32(3):595\u2013628 vii.","DOI":"10.1016\/j.ncl.2014.04.007"},{"key":"174_CR31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/B978-0-444-63432-0.00025-6","volume":"133","author":"A Mammen","year":"2016","unstructured":"Mammen A. Autoimmune muscle disease. Handb Clin Neurol. 2016;133:467\u201384.","journal-title":"Handb Clin Neurol"},{"issue":"17","key":"174_CR32","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMc1506163","volume":"373","author":"AL Mammen","year":"2015","unstructured":"Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015;373(17):1680\u20132.","journal-title":"N Engl J Med"},{"key":"174_CR33","first-page":"1","volume":"5","author":"R Aggarwal","year":"2019","unstructured":"Aggarwal R, Moghadam-Kia S, Lacomis D, Malik A, Qi Z, Koontz D, et al. Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level. Scand J Rheumatol. 2019;5:1\u20137.","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"174_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13075-019-2093-6","volume":"22","author":"A Meyer","year":"2020","unstructured":"\u2022\u2022 Meyer A, Troyanov Y, Drouin J, Oligny-Longpr\u00e9 G, Landon-Cardinal O, Hoa S, et al. Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Res Ther. 2020;22(1):5 This retrospective study demonstrated the importance of avoiding delays in treatment in order to achieve disease remission.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"174_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/acr.22920","volume":"69","author":"I Pinal-Fernandez","year":"2017","unstructured":"Pinal-Fernandez I, Parks C, Werner JL, Albayda J, Paik J, Danoff SK, et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res. 2017;69(2):263\u201370.","journal-title":"Arthritis Care Res"},{"issue":"7","key":"174_CR36","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMra1515161","volume":"374","author":"AL Mammen","year":"2016","unstructured":"Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374(7):664\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"174_CR37","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/BOR.0000000000000438","volume":"29","author":"E Tiniakou","year":"2017","unstructured":"Tiniakou E, Christopher-Stine L. Immune-mediated necrotizing myopathy associated with statins: history and recent developments. Curr Opin Rheumatol. 2017;29(6):604\u201311.","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"174_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0828-282X(06)70253-7","volume":"22","author":"C Simard","year":"2006","unstructured":"Simard C, Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can J Cardiol. 2006;22(2):141\u20134.","journal-title":"Can J Cardiol"},{"issue":"10","key":"174_CR39","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/art.40919","volume":"71","author":"E Tiniakou","year":"2019","unstructured":"\u2022\u2022 Tiniakou E, Rivera E, Mammen AL, Christopher-Stine L. Use of proprotein convertase subtilisin\/kexin type 9 inhibitors in statin-associated immune-mediated necrotizing myopathy: a case series. Arthritis Rheumatol. 2019;71(10):1723\u20136 This case-series exhibited the safety of PCSK9 inhibitors as cholesterol-lowering treatment strategy in patients with anti-HMGCR IMNM.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"174_CR40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jcp.22130","volume":"224","author":"H Lan","year":"2010","unstructured":"Lan H, Pang L, Smith MM, Levitan D, Ding W, Liu L, et al. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells. J Cell Physiol. 2010;224(1):273\u201381.","journal-title":"J Cell Physiol"},{"issue":"3","key":"174_CR41","doi-asserted-by":"publisher","first-page":"310","DOI":"10.7150\/ijbs.3524","volume":"8","author":"L Zhang","year":"2012","unstructured":"Zhang L, McCabe T, Condra JH, Ni YG, Peterson LB, Wang W, et al. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci. 2012;8(3):310\u201327.","journal-title":"Int J Biol Sci"},{"issue":"9","key":"174_CR42","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/acr.20219","volume":"62","author":"R Valiyil","year":"2010","unstructured":"Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res. 2010;62(9):1328\u201334.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"174_CR43","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/rheumatology\/ket251","volume":"53","author":"K Maeshima","year":"2014","unstructured":"Maeshima K, Kiyonaga Y, Imada C, Iwakura M, Hamasaki H, Haranaka M, et al. Successful treatment of refractory anti-signal recognition particle myopathy using abatacept. Rheumatology (Oxford). 2014;53(2):379\u201380.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"174_CR44","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000381","volume":"4","author":"CA Mecoli","year":"2017","unstructured":"Mecoli CA, Lahouti AH, Brodsky RA, Mammen AL, Christopher-Stine L. High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e381.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"174_CR45","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1212\/NXI.0000000000000096","volume":"2","author":"S Ramanathan","year":"2015","unstructured":"Ramanathan S, Langguth D, Hardy TA, Garg N, Bundell C, Rojana-Udomsart A, et al. Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e96.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"174_CR46","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.nmd.2006.03.002","volume":"16","author":"J-B Arlet","year":"2006","unstructured":"Arlet J-B, Dimitri D, Pagnoux C, Boyer O, Maisonobe T, Authier F-J, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord. 2006;16(5):334\u20136.","journal-title":"Neuromuscul Disord"},{"issue":"21","key":"174_CR47","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","volume":"326","author":"FW Miller","year":"1992","unstructured":"Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992;326(21):1380\u20134.","journal-title":"N Engl J Med"},{"issue":"11","key":"174_CR48","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/rheumatology\/ker292","volume":"50","author":"GEA Habers","year":"2011","unstructured":"Habers GEA, Takken T. Safety and efficacy of exercise training in patients with an idiopathic inflammatory myopathy\u2014a systematic review. Rheumatology. 2011;50(11):2113\u201324.","journal-title":"Rheumatology."},{"issue":"12","key":"174_CR49","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/acr.22068","volume":"65","author":"L Alemo Munters","year":"2013","unstructured":"Alemo Munters L, Dastmalchi M, Andgren V, Emilson C, Bergeg\u00e5rd J, Regardt M, et al. Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension follow-up. Arthritis Care Res. 2013;65(12):1959\u201368.","journal-title":"Arthritis Care Res"},{"issue":"9","key":"174_CR50","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1021\/acs.jafc.5b05571","volume":"64","author":"A Gil-Ram\u00edrez","year":"2016","unstructured":"Gil-Ram\u00edrez A, Caz V, Smiderle FR, Martin-Hernandez R, Largo C, Tabernero M, et al. Water-soluble compounds from Lentinula edodes influencing the HMG-CoA reductase activity and the expression of genes involved in the cholesterol metabolism. J Agric Food Chem. 2016;64(9):1910\u201320.","journal-title":"J Agric Food Chem"},{"issue":"6","key":"174_CR51","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1039\/C5FO00362H","volume":"6","author":"L Zeng","year":"2015","unstructured":"Zeng L, Yan J, Luo L, Zhang D. Effects of Pu-erh tea aqueous extract (PTAE) on blood lipid metabolism enzymes. Food Funct. 2015;6(6):2008\u201316.","journal-title":"Food Funct"},{"issue":"8","key":"174_CR52","doi-asserted-by":"publisher","first-page":"852","DOI":"10.7164\/antibiotics.32.852","volume":"32","author":"A Endo","year":"1979","unstructured":"Endo A, Monacolin K. A new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo). 1979;32(8):852\u20134.","journal-title":"J Antibiot (Tokyo)"},{"issue":"2","key":"174_CR53","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/mus.24541","volume":"52","author":"V Limaye","year":"2015","unstructured":"Limaye V, Bundell C, Hollingsworth P, Rojana-Udomsart A, Mastaglia F, Blumbergs P, et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve. 2015;52(2):196\u2013203.","journal-title":"Muscle Nerve"},{"issue":"6","key":"174_CR54","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000290","volume":"3","author":"M Kadoya","year":"2016","unstructured":"Kadoya M, Hida A, Hashimoto Maeda M, Taira K, Ikenaga C, Uchio N, et al. Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm. 2016;3(6):e290.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"174_CR55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/ard.59.2.141","volume":"59","author":"GJ Hengstman","year":"2000","unstructured":"Hengstman GJ, van Venrooij WJ, Vencovsky J, Moutsopoulos HM, van Engelen BG. The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis. 2000;59(2):141\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"174_CR56","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.2169\/internalmedicine.2564-18","volume":"58","author":"S Takeguchi-Kikuchi","year":"2019","unstructured":"Takeguchi-Kikuchi S, Hayasaka T, Katayama T, Kano K, Takahashi K, Saito T, et al. Anti-signal recognition particle antibody-positive necrotizing myopathy with secondary cardiomyopathy: the first myocardial biopsy- and multimodal imaging-proven case. Intern Med. 2019;58(21):3189\u201394.","journal-title":"Intern Med"},{"issue":"4","key":"174_CR57","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","volume":"92","author":"LG Rider","year":"2013","unstructured":"Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(4):223\u201343.","journal-title":"Medicine (Baltimore)"}],"container-title":["Current Treatment Options in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40674-021-00174-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40674-021-00174-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40674-021-00174-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T07:35:15Z","timestamp":1698132915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40674-021-00174-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1007\/s40674-021-00174-1","relation":{},"ISSN":["2198-6002"],"issn-type":[{"value":"2198-6002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,29]]},"assertion":[{"value":"11 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Emma Weeding declares that he has no conflict of interest. Eleni Tiniakou declares that he has no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}